David B Buckley
Overview
Explore the profile of David B Buckley including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
508
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kenny J, Ramsden D, Buckley D, Dallas S, Fung C, Mohutsky M, et al.
Drug Metab Dispos
. 2018 Jul;
46(9):1285-1303.
PMID: 29959133
The Innovation and Quality Induction Working Group presents an assessment of best practice for data interpretation of in vitro induction, specifically, response thresholds, variability, application of controls, and translation to...
2.
Kazmi F, Yerino P, McCoy C, Parkinson A, Buckley D, Ogilvie B
Drug Metab Dispos
. 2018 May;
46(8):1066-1074.
PMID: 29735754
Oligonucleotides represent an expanding class of pharmacotherapeutics in development for various indications. Typically, oligonucleotides are developed with phosphorothioate linkages for the improvement of biologic stability; however, limited data are available...
3.
Vermeer L, Isringhausen C, Ogilvie B, Buckley D
Drug Metab Dispos
. 2015 Dec;
44(3):453-9.
PMID: 26668209
Ketoconazole is a potent CYP3A4/5 inhibitor and, until recently, recommended by the Food and Drug Administration (FDA) and the European Medicines Agency as a strong CYP3A4/5 inhibitor in clinical drug-drug...
4.
Haupt L, Kazmi F, Ogilvie B, Buckley D, Smith B, Leatherman S, et al.
Drug Metab Dispos
. 2015 Sep;
43(11):1744-50.
PMID: 26354951
In the present study, we conducted a retrospective analysis of 343 in vitro experiments to ascertain whether observed (experimentally determined) values of Ki for reversible cytochrome P450 (P450) inhibition could...
5.
Czerwinski M, Kazmi F, Parkinson A, Buckley D
Drug Metab Dispos
. 2014 Oct;
43(1):42-52.
PMID: 25326287
Like most infections and certain inflammatory diseases, some therapeutic proteins cause a cytokine-mediated suppression of hepatic drug-metabolizing enzymes, which may lead to pharmacokinetic interactions with small-molecule drugs. We propose a...
6.
Kazmi F, Haupt L, Horkman J, Smith B, Buckley D, Wachter E, et al.
Xenobiotica
. 2014 Jan;
44(7):606-14.
PMID: 24405273
1. Rose bengal (4,5,6,7-tetrachloro-2',4',5',7'-tetraiodofluorescein) is being developed for the treatment of cutaneous melanoma and hepatocellular carcinoma. Interestingly, rose bengal can generate singlet oxygen species upon exposure to light. 2. We...
7.
Barbara J, Buckley D, Horrigan M
Bioanalysis
. 2013 Jun;
5(10):1211-28.
PMID: 23721444
Background: The utility of high-resolution MS (HRMS) with post-acquisition data mining in DMPK goes much further than the now established approach to simultaneously acquire quantitative and qualitative information for lead...
8.
More V, Cheng Q, Donepudi A, Buckley D, Lu Z, Cherrington N, et al.
Drug Metab Dispos
. 2013 Mar;
41(5):1148-55.
PMID: 23462698
Unsafe use of alcohol results in approximately 2.5 million deaths worldwide, with cirrhosis contributing to 16.6% of reported deaths. Serum insulin levels are often elevated in alcoholism and may result...
9.
Barbara J, Kazmi F, Parkinson A, Buckley D
Drug Metab Dispos
. 2013 Feb;
41(5):1012-22.
PMID: 23404373
Metabolism-dependent inhibition (MDI) of cytochrome P450 (P450) enzymes has the potential to cause clinically relevant drug-drug interactions. In the case of several alkylamine drugs, MDI of P450 involves formation of...
10.
Kazmi F, Hensley T, Pope C, Funk R, Loewen G, Buckley D, et al.
Drug Metab Dispos
. 2013 Feb;
41(4):897-905.
PMID: 23378628
Lipophilic (logP > 1) and amphiphilic drugs (also known as cationic amphiphilic drugs) with ionizable amines (pKa > 6) can accumulate in lysosomes, a process known as lysosomal trapping. This...